Arovella Therapeutics (ASX: ALA)

Currency in -

Last close As at 07/06/2023


−0.01 (−25.00%)

Market capitalisation


Arovella Therapeutics is a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system.



Balance Sheet

Forecast net debt (A$m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual (5.6) 36.0 (15.0)
Relative 0.6 39.5 (11.6)
52 week high/low A$0.0/A$0.0


Edison Investment Research is terminating coverage on Arovella Therapeutics. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (c) P/E (x) P/CF (x)
2021A 0.3 (3.1) (3.4) (1.15) N/A N/A
2022A 0.3 (7.0) (7.4) (1.42) N/A N/A
2023E N/A N/A N/A N/A N/A N/A
2024E N/A N/A N/A N/A N/A N/A

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free